Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer

JAMA

Volumn 303, Issue 11, 2010, Pages 1046-1053

  Talcott, James A ^a,f   Rossi, Carl ^b   Shipley, William U ^c,f   Clark, Jack A ^d,e   Slater, Jerry D ^b   Niemierko, Andrzej ^c,f   Zietman, Anthony L ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER IRRITATION; CANCER GROWTH; CANCER SURVIVOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; ENTEROPATHY; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MICTURITION; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT DECISION MAKING; PHOTON THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

EID: 77949500929     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.287     Document Type: Article

References (31)

1. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004; 100(3):538-543.
2. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129-135.
3. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21(21):3979-3986.
4. Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys. 1998;41(3):501-510.
5. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol. 2001; 59(1):65-70.
6. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353(9149):267-272.
7. Loeffler JS, Smith AR, Suit HD. The potential role of proton beams in radiation oncology. Semin Oncol. 1997;24(6):686-695.
8. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953-964.
9. Benk VA, Adams JA, Shipley WU, et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys. 1993; 26(3):551-557.
10. Yonemoto LT, Slater JD, Rossi CJ Jr, et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1997;37(1):21-29.
11. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233-1239.
12. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106-1111.
13. Lawton CA, Won M, Pilepich MV, et al. Longterm treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21(4):935-939.
14. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32(1):3-12.
15. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39(10):1118-1130.
16. Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care. 2003; 41(8):923-936.
17. Stewart A, Ware J Jr. Measuring Function Status and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
18. Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol. 2006;176(4 pt 1): 1558-1563.
19. Do YK, Carpenter WR, Spain P, et al. Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control. 2010;21(1): 31-40.
20. Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer. 2007;109(11):2229-2238.
21. Papoulis A. Probability, Random Variables, and Stochastic Processes. 3rd ed. New York, NY: McGraw-Hill; 1991.
22. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167(1): 123-126.
23. Garg AK, Mai WY, McGary JE, GrantWH III, Butler EB, Teh BS. Radiation proctopathy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66(5):1294-1305.
24. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003;62(4): 707-713.
25. Mangar SA, Sydes MR, Tucker HL, et al;MRCRT01 Trial Management Group. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006;80(3):355-362.
26. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072-1083.
27. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916-3922.
28. Clark JA, Talcott JA. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. J Clin Oncol. 2006;24(27): 4457-4463.
29. Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients' perceptions of the side-effects of prostate cancer treatment-a qualitative interview study. Soc Sci Med. 2006;63(4):911-919.
30. Yu CL, Fielding R, Chan CL. The mediating role of optimism on post-radiation quality of life in nasopharyngeal carcinoma. Qual Life Res. 2003;12 (1):41-51.
31. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on costeffectiveness in health and medicine. JAMA. 1996; 276(15):1253-1258.